Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RAPP

Rapport Therapeutics Inc

Dec 13 • 03:29PM ET

18.52

Dollar change -0.49
Percentage change -2.58	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX BLUE REGN SAGE NBIX ACAD MRNA CRSP EDIT

| Held by: VTI IWM VXF VTWO IWO SCHA IWN IWC SCHB VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	52.23%	Shs Outstand	36.58M	Perf Week	-9.48%
Market Cap	677.46M	Forward P/E	-	EPS next Y	-	Insider Trans	0.23%	Shs Float	17.47M	Perf Month	-15.24%
Income	-	PEG	-	EPS next Q	-0.64	Inst Own	54.55%	Short Float	10.25%	Perf Quarter	-1.44%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	20.50%	Short Ratio	11.89	Perf Half Y	-23.79%
Book/sh	8.83	P/B	2.10	EPS next Y	-	ROA	-	Short Interest	1.79M	Perf Year	-
Cash/sh	8.77	P/C	2.11	EPS next 5Y	-	ROE	-	52W Range	16.55 - 29.74	Perf YTD	-10.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-37.73%	Beta	-
Dividend TTM	-	Quick Ratio	45.91	Sales past 5Y	0.00%	Gross Margin	-	52W Low	11.90%	ATR (14)	1.75
Dividend Ex-Date	-	Current Ratio	45.91	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	35.62	Volatility	6.30% 8.60%
Employees	58	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	37.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-185.25%	Payout	-	Rel Volume	0.68	Prev Close	19.01
Sales Surprise	-	EPS Surprise	11.35%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	150.62K	Price	18.52
SMA20	-13.33%	SMA50	-19.98%	SMA200	-16.77%	Trades		Volume	94,771	Change	-2.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Dec-06-24 12:01PM	Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures (GlobeNewswire)
Nov-14-24 07:00AM	Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-08-24 07:18AM	Rapport Therapeutics expects cash to fund requirements through 2026 (TipRanks)
Nov-07-24 07:00AM	Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update (GlobeNewswire)
Nov-04-24 07:00AM	Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
07:00AM	Loading…
Sep-05-24 07:00AM	Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences (GlobeNewswire)
Aug-29-24 07:00AM	Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Aug-08-24 07:00AM	Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update (GlobeNewswire)
Aug-06-24 06:30AM	3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns (InvestorPlace)
Jul-29-24 07:00AM	Rapport Therapeutics to Present Data for TARP 8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain (GlobeNewswire)
Jul-05-24 02:22PM	Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More (Insider Monkey)
Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HEALY JAMES	Director	Jul 01 '24	Buy	24.52	44,032	1,079,575	40,851	Jul 03 08:04 PM
HEALY JAMES	Director	Jun 10 '24	Buy	17.00	558,824	9,500,008	1,863,327	Jun 10 07:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RAPP

Rapport Therapeutics Inc

Upgrade your FINVIZ experience